PubRank

Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

PubWeight™: 1.19‹?› | Rank: Top 10%

🔗 View Article (PMC 4321900)

Published in Nat Commun on September 23, 2014

Authors

Maya Ghoussaini1, Stacey L Edwards2, Kyriaki Michailidou3, Silje Nord4, Richard Cowper-Sal Lari5, Kinjal Desai6, Siddhartha Kar3, Kristine M Hillman2, Susanne Kaufmann2, Dylan M Glubb7, Jonathan Beesley7, Joe Dennis3, Manjeet K Bolla3, Qin Wang3, Ed Dicks1, Qi Guo1, Marjanka K Schmidt8, Mitul Shah1, Robert Luben3, Judith Brown3, Kamila Czene9, Hatef Darabi9, Mikael Eriksson9, Daniel Klevebring9, Stig E Bojesen10, Børge G Nordestgaard10, Sune F Nielsen11, Henrik Flyger12, Diether Lambrechts13, Bernard Thienpont14, Patrick Neven15, Hans Wildiers15, Annegien Broeks8, Laura J Van't Veer8, Emiel J Th Rutgers8, Fergus J Couch16, Janet E Olson17, Emily Hallberg17, Celine Vachon17, Jenny Chang-Claude18, Anja Rudolph18, Petra Seibold18, Dieter Flesch-Janys19, Julian Peto20, Isabel Dos-Santos-Silva20, Lorna Gibson20, Heli Nevanlinna21, Taru A Muranen21, Kristiina Aittomäki22, Carl Blomqvist23, Per Hall9, Jingmei Li24, Jianjun Liu24, Keith Humphreys9, Daehee Kang25, Ji-Yeob Choi26, Sue K Park25, Dong-Young Noh27, Keitaro Matsuo28, Hidemi Ito29, Hiroji Iwata30, Yasushi Yatabe31, Pascal Guénel32, Thérèse Truong32, Florence Menegaux32, Marie Sanchez32, Barbara Burwinkel33, Frederik Marme34, Andreas Schneeweiss34, Christof Sohn35, Anna H Wu36, Chiu-Chen Tseng36, David Van Den Berg36, Daniel O Stram36, Javier Benitez37, M Pilar Zamora38, Jose Ignacio Arias Perez39, Primitiva Menéndez40, Xiao-Ou Shu41, Wei Lu42, Yu-Tang Gao43, Qiuyin Cai41, Angela Cox44, Simon S Cross45, Malcolm W R Reed44, Irene L Andrulis46, Julia A Knight47, Gord Glendon48, Sandrine Tchatchou49, Elinor J Sawyer50, Ian Tomlinson51, Michael J Kerin52, Nicola Miller52, Christopher A Haiman53, Brian E Henderson53, Fredrick Schumacher53, Loic Le Marchand54, Annika Lindblom55, Sara Margolin56, Soo Hwang Teo57, Cheng Har Yip58, Daphne S C Lee59, Tien Y Wong60, Maartje J Hooning61, John W M Martens61, J Margriet Collée62, Carolien H M van Deurzen63, John L Hopper64, Melissa C Southey65, Helen Tsimiklis65, Miroslav K Kapuscinski64, Chen-Yang Shen66, Pei-Ei Wu67, Jyh-Cherng Yu68, Shou-Tung Chen69, Grethe Grenaker Alnæs4, Anne-Lise Borresen-Dale70, Graham G Giles71, Roger L Milne72, Catriona McLean73, Kenneth Muir74, Artitaya Lophatananon75, Sarah Stewart-Brown75, Pornthep Siriwanarangsan76, Mikael Hartman77, Hui Miao78, Shaik Ahmad Bin Syed Buhari79, Yik Ying Teo80, Peter A Fasching81, Lothar Haeberle82, Arif B Ekici83, Matthias W Beckmann82, Hermann Brenner84, Aida Karina Dieffenbach84, Volker Arndt85, Christa Stegmaier86, Anthony Swerdlow87, Alan Ashworth88, Nick Orr88, Minouk J Schoemaker89, Montserrat García-Closas90, Jonine Figueroa91, Stephen J Chanock91, Jolanta Lissowska92, Jacques Simard93, Mark S Goldberg94, France Labrèche95, Martine Dumont93, Robert Winqvist96, Katri Pylkäs96, Arja Jukkola-Vuorinen97, Hiltrud Brauch98, Thomas Brüning99, Yon-Dschun Koto100, Paolo Radice101, Paolo Peterlongo102, Bernardo Bonanni103, Sara Volorio104, Thilo Dörk105, Natalia V Bogdanova106, Sonja Helbig105, Arto Mannermaa107, Vesa Kataja108, Veli-Matti Kosma107, Jaana M Hartikainen107, Peter Devilee109, Robert A E M Tollenaar110, Caroline Seynaeve111, Christi J Van Asperen62, Anna Jakubowska112, Jan Lubinski112, Katarzyna Jaworska-Bieniek112, Katarzyna Durda112, Susan Slager17, Amanda E Toland113, Christine B Ambrosone114, Drakoulis Yannoukakos115, Suleeporn Sangrajrang116, Valerie Gaborieau117, Paul Brennan117, James McKay117, Ute Hamann118, Diana Torres119, Wei Zheng41, Jirong Long41, Hoda Anton-Culver120, Susan L Neuhausen121, Craig Luccarini1, Caroline Baynes1, Shahana Ahmed1, Mel Maranian1, Catherine S Healey1, Anna González-Neira122, Guillermo Pita122, M Rosario Alonso122, Nuria Alvarez122, Daniel Herrero122, Daniel C Tessier123, Daniel Vincent124, Francois Bacot124, Ines de Santiago125, Jason Carroll125, Carlos Caldas125, Melissa A Brown126, Mathieu Lupien127, Vessela N Kristensen128, Paul D P Pharoah129, Georgia Chenevix-Trench7, Juliet D French2, Douglas F Easton129, Alison M Dunning1, Australian Ovarian Cancer Management Group, Australian Ovarian Cancer Management Group

Author Affiliations

1: Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK.
2: 1] Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia [2] School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia.
3: Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.
4: Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, N-0310 Oslo, Norway.
5: The Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada M5T 2M9.
6: 1] The Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada M5T 2M9 [2] Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire 03755, USA.
7: Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia.
8: Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, 1066 CX Amsterdam, The Netherlands.
9: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm SE-17177, Sweden.
10: 1] Copenhagen General Population Study, Herlev Hospital, 2730 Herlev, Copenhagen, Denmark [2] Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Copenhagen, Denmark [3] Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
11: 1] Copenhagen General Population Study, Herlev Hospital, 2730 Herlev, Copenhagen, Denmark [2] Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Copenhagen, Denmark.
12: Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Copenhagen, Denmark.
13: 1] Laboratory for Translational Genetics, Department of Oncology, University of Leuven, 3000 Leuven, Belgium [2] Vesalius Research Center (VRC), VIB, 3000 Leuven, Belgium.
14: 1] Vesalius Research Center (VRC), VIB, 3000 Leuven, Belgium [2] Vesalius Research Center, University of Leuven, 3000 Leuven, Belgium.
15: 1] Department of Oncology, University of Leuven, 3000 Leuven, Belgium [2] Multidisciplinary Breast Center, Department of General Medical Oncology, University Hospitals Leuven, 3000 Leuven, Belgium.
16: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.
17: Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA.
18: Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
19: Department of Cancer Epidemiology/Clinical Cancer Registry and Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, 20246 Hamburg, Germany.
20: Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
21: Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, FI-00029 HUS, Finland.
22: Department of Clinical Genetics, University of Helsinki, Helsinki University Central Hospital, Helsinki, FI-00029 HUS, Finland.
23: Department of Oncology, University of Helsinki, Helsinki University Central Hospital, Helsinki, FI-00029 HUS, Finland.
24: Human Genetics Division, Genome Institute of Singapore, Singapore 138672, Singapore.
25: 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Korea [2] Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 151-742, Korea [3] Department of Preventive Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea.
26: 1] Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Korea [2] Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 151-742, Korea.
27: Department of Surgery, Seoul National University College of Medicine, Seoul 110-799, Korea.
28: Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka 812-8582, Japan.
29: Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi 464-8681, Japan.
30: Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya 484-8681, Japan.
31: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya 484-8681, Japan.
32: 1] Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, 94807 Villejuif, France [2] University Paris-Sud, UMRS 1018, 94807 Villejuif, France.
33: 1] Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany [2] Molecular Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
34: 1] Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany [2] National Center for Tumor Diseases, University of Heidelberg, 69120 Heidelberg, Germany.
35: Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany.
36: Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
37: 1] Centro de Investigación en Red de Enfermedades Raras (CIBERER), 46010 Valencia, Spain [2] Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
38: Servicio de Oncología Médica, Hospital Universitario La Paz, 28046 Madrid, Spain.
39: Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, 33012 Oviedo, Spain.
40: Servicio de Anatomía Patológica, Hospital Monte Naranco, 33013 Oviedo, Spain.
41: Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA.
42: Shanghai Center for Disease Control and Prevention, Shanghai 200336, China.
43: Department of Epidemiology, Shanghai Cancer Institute, Shanghai 200032, China.
44: CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield S10 2RX, UK.
45: Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.
46: 1] Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5 [2] Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada M5S 1A8.
47: 1] Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada M5T 3M7 [2] Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5.
48: Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5.
49: Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5.
50: Division of Cancer Studies, NIHR Comprehensive Biomedical Research Centre, Guy's &St Thomas' NHS Foundation Trust in partnership with King's College London, London SE1 9RT, UK.
51: Wellcome Trust Centre for Human Genetics, Oxford Biomedical Research Centre, University of Oxford, Oxford OX3 7BN, UK.
52: Clinical Science Institute, University Hospital Galway, Galway, Ireland.
53: Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
54: Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii 96813, USA.
55: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm SE-17177, Sweden.
56: Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-17177, Sweden.
57: 1] Breast Cancer Research Unit, University Malaya Cancer Research Institute, University Malaya Medical Centre, 59100 Kuala Lumpur, Malaysia [2] Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya 47500 Selangor, Malaysia.
58: Breast Cancer Research Unit, University Malaya Cancer Research Institute, University Malaya Medical Centre, 59100 Kuala Lumpur, Malaysia.
59: Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya 47500 Selangor, Malaysia.
60: Singapore Eye Research Institute, National University of Singapore, Singapore 168751, Singapore.
61: Department of Medical Oncology, Erasmus MC Cancer Institute, 3008 AE Rotterdam, The Netherlands.
62: Department of Clinical Genetics, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands.
63: Department of Pathology, Erasmus University Medical Center, 3075 EA Rotterdam, The Netherlands.
64: Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, Melbourne School of Population Health, University of Melbourne, Melbourne, Victoria 3010, Australia.
65: Department of Pathology, The University of Melbourne, Melbourne, Victoria 3010, Australia.
66: 1] College of Public Health, China Medical University, Taichung 40402, Taiwan, China [2] Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan, China.
67: Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan, China.
68: Department of Surgery, Tri-Service General Hospital, Taipei 114, Taiwan, China.
69: Department of Surgery, Changhua Christian Hospital, Changhua City 500, Taiwan, China.
70: 1] Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, N-0310 Oslo, Norway [2] Institute of Clinical Medicine, University of Oslo (UiO), 0318 Oslo, Norway.
71: 1] Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria 3004, Australia [2] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria 3010, Australia.
72: 1] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria 3010, Australia [2] Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria 3053, Australia.
73: Anatomical Pathology, The Alfred Hospital, Melbourne, Victoria 3004, Australia.
74: 1] Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK [2] Institute of Population Health, University of Manchester, Manchester M13 9PL, UK.
75: Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK.
76: Ministry of Public Health, Bangkok 10400, Thailand.
77: 1] Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore 119228, Singapore [2] Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117597, Singapore.
78: Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117597, Singapore.
79: Division of General Surgery, National University Health System, Singapore 117597, Singapore.
80: 1] Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117597, Singapore [2] Department of Statistics and Applied Probability, National University of Singapore, Singapore 117546, Singapore.
81: 1] Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA [2] Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
82: Department of Gynecology and Obstetrics, University Breast Center Franconia, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
83: Institute of Human Genetics, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
84: 1] Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany [2] German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
85: Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
86: Saarland Cancer Registry, 66119 Saarbrücken, Germany.
87: 1] Division of Breast Cancer Research, Institute of Cancer Research, London SM2 5NG, UK [2] Division of Genetics and Epidemiology, Institute of Cancer Research, London SM2 5NG, UK.
88: Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London SW3 6JB, UK.
89: Division of Genetics and Epidemiology, Institute of Cancer Research, London SM2 5NG, UK.
90: 1] Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London SW3 6JB, UK [2] Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.
91: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20850, USA.
92: Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland.
93: Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Quebec, Canada G1V 4G2.
94: 1] Department of Medicine, McGill University, Montreal, Quebec, Canada H3G 2M1 [2] Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada H3A 1A8.
95: Département de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, Quebec, Canada H3T 1A8.
96: Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, NordLab Oulu/Oulu University Hospital, University of Oulu, FI-90220 Oulu, Finland.
97: Department of Oncology, Oulu University Hospital, University of Oulu, FI-90220 Oulu, Finland.
98: 1] Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, 70376 Stuttgart, Germany [2] University of Tübingen, 72074 Tübingen, Germany [3] German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
99: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), 44789 Bochum, Germany.
100: Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, 53113 Bonn, Germany.
101: Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), 20133 Milan, Italy.
102: IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, 20139 Milan, Italy.
103: Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), 20141 Milan, Italy.
104: 1] IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, 20139 Milan, Italy [2] Cogentech Cancer Genetic Test Laboratory, 20133 Milan, Italy.
105: Department of Obstetrics and Gynaecology, Hannover Medical School, 30625 Hannover, Germany.
106: Department of Radiation Oncology, Hannover Medical School, 30625 Hannover, Germany.
107: 1] Cancer Center of Eastern Finland, University of Eastern Finland, FI-70211 Kuopio, Finland [2] Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, FI-70210 Kuopio, Finland [3] School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern Finland, FI-70211 Kuopio, Finland.
108: 1] Cancer Center of Eastern Finland, University of Eastern Finland, FI-70211 Kuopio, Finland [2] School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern Finland, FI-70211 Kuopio, Finland.
109: Department of Human Genetics &Department of Pathology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
110: Department of Surgical Oncology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
111: Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Centre, 3075 EA Rotterdam, The Netherlands.
112: Department of Genetics and Pathology, Pomeranian Medical University, 70-115 Szczecin, Poland.
113: Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA.
114: Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
115: Molecular Diagnostics Laboratory, IRRP, National Centre for Scientific Research 'Demokritos', Aghia Paraskevi Attikis, Athens 15310, Greece.
116: National Cancer Institute, Bangkok 10400, Thailand.
117: International Agency for Research on Cancer, Lyon, Cedex 08, France.
118: Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
119: 1] Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany [2] Institute of Human Genetics, Pontificia University Javeriana, Bogota, DC 11001000, Colombia.
120: Department of Epidemiology, University of California Irvine, Irvine, California 92697, USA.
121: Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California 92697, USA.
122: Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
123: Centre d'innovation Génome Québec et Université McGill, Montréal, Quebec, Canada H3A OG1.
124: McGill University, Montreal, Quebec, Canada H3A OG1.
125: Cancer Research UK, Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
126: School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia.
127: 1] The Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada M5T 2M9 [2] Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5 [3] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5G 1L7.
128: 1] Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, N-0310 Oslo, Norway [2] Institute of Clinical Medicine, University of Oslo (UiO), 0318 Oslo, Norway [3] Department of Clinical Molecular Biology (EpiGen), University of Oslo (UiO), 0450 Oslo, Norway.
129: 1] Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK [2] Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.

Articles citing this ↘

Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. Am J Hum Genet (2014) 1.00

Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. Am J Hum Genet (2015) 1.00

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet (2016) 0.92

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget (2016) 0.90

Strategies for fine-mapping complex traits. Hum Mol Genet (2015) 0.88

Gene-environment interaction and risk of breast cancer. Br J Cancer (2016) 0.83

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun (2016) 0.82

Five endometrial cancer risk loci identified through genome-wide association analysis. Nat Genet (2016) 0.80

Downregulation of the Ca(2+)-activated K(+) channel KC a3.1 by histone deacetylase inhibition in human breast cancer cells. Pharmacol Res Perspect (2016) 0.78

Interaction between Common Breast Cancer Susceptibility Variants, Genetic Ancestry, and Nongenetic Risk Factors in Hispanic Women. Cancer Epidemiol Biomarkers Prev (2015) 0.78

Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocr Relat Cancer (2015) 0.78

The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression. Ann Rheum Dis (2015) 0.78

IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiology. J Cell Commun Signal (2015) 0.77

Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. Am J Hum Genet (2016) 0.77

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol (2017) 0.76

Identification of Differentially Expressed IGFBP5-Related Genes in Breast Cancer Tumor Tissues Using cDNA Microarray Experiments. Genes (Basel) (2015) 0.76

Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiol Biomarkers Prev (2015) 0.76

A functional variant rs4442975 modulating FOXA1-binding affinity does not influence the risk or progression of breast cancer in Chinese Han population. Oncotarget (2016) 0.75

An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Hum Mol Genet (2016) 0.75

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst (2017) 0.75

Expression Quantitative Trait loci (QTL) in tumor adjacent normal breast tissue and breast tumor tissue. PLoS One (2017) 0.75

Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast. Int J Cancer (2016) 0.75

Deep targeted sequencing of 12 breast cancer susceptibility regions in 4611 women across four different ethnicities. Breast Cancer Res (2016) 0.75

Long-Range Modulation of PAG1 Expression by 8q21 Allergy Risk Variants. Am J Hum Genet (2015) 0.75

Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. Cancer Discov (2016) 0.75

A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. Am J Hum Genet (2016) 0.75

Functional dissection of breast cancer risk-associated TERT promoter variants. Oncotarget (2017) 0.75

Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. Int J Cancer (2017) 0.75

Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage. Am J Hum Genet (2017) 0.75

Articles cited by this ↗

The ENCODE (ENCyclopedia Of DNA Elements) Project. Science (2004) 38.24

Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet (2001) 22.07

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47

Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2007) 10.81

Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell (2002) 8.59

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82

FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet (2010) 5.22

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88

Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet (2012) 2.86

Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet (2013) 2.67

Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem (1997) 2.40

Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24

Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res (2013) 2.14

Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J (2006) 1.77

Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol (2011) 1.55

Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem (2003) 1.43

Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39

Genotyping with TaqMAMA. Genomics (2004) 1.34

Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets (2013) 1.18

Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem (1999) 1.11

Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development (2002) 1.05

IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells. J Cell Sci (2012) 1.02

Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chin J Cancer (2012) 1.01

IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo. FASEB J (2009) 0.96

Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res (1992) 0.95

In vivo regulation of the insulin-like growth factor system of mitogens by human chorionic gonadotropin. Int J Oncol (1998) 0.80

Articles by these authors ⇆

Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22

Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet (2014) 1.05

Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. Am J Hum Genet (2014) 1.00

Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. Am J Hum Genet (2015) 1.00

Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun (2014) 1.00

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet (2016) 0.95

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun (2016) 0.89

Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis (2015) 0.88

Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Hum Mol Genet (2015) 0.88

2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun (2014) 0.87